122 related articles for article (PubMed ID: 29296374)
61. Prognositc significance of SUV
Dong M; Liu J; Sun X; Xing L
J Med Imaging Radiat Oncol; 2017 Oct; 61(5):652-659. PubMed ID: 28266166
[TBL] [Abstract][Full Text] [Related]
62. Automated detection, delineation and quantification of whole-body bone metastasis using FDG-PET/CT images.
Nigam R; Field M; Harris G; Barton M; Carolan M; Metcalfe P; Holloway L
Phys Eng Sci Med; 2023 Jun; 46(2):851-863. PubMed ID: 37126152
[TBL] [Abstract][Full Text] [Related]
63. Predictive Value of Baseline FDG-PET/CT for the Durable Response to Immune Checkpoint Inhibition in NSCLC Patients Using the Morphological and Metabolic Features of Primary Tumors.
Kudura K; Ritz N; Kutzker T; Hoffmann MHK; Templeton AJ; Foerster R; Kreissl MC; Antwi K
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551581
[TBL] [Abstract][Full Text] [Related]
64. Stereotactic Body Radiotherapy for Medically Inoperable Stage I-II Non-Small Cell Lung Cancer: The Mayo Clinic Experience.
Hobbs CJ; Ko SJ; Paryani NN; Accurso JM; Olivier KR; Garces YI; Park SS; Hallemeier CL; Schild SE; Vora SA; Ashman JB; Rule WG; Bowers JR; Heckman MG; Diehl NN; Miller RC
Mayo Clin Proc Innov Qual Outcomes; 2018 Mar; 2(1):40-48. PubMed ID: 30225431
[TBL] [Abstract][Full Text] [Related]
65. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.
Gayed I; Vu T; Iyer R; Johnson M; Macapinlac H; Swanston N; Podoloff D
J Nucl Med; 2004 Jan; 45(1):17-21. PubMed ID: 14734662
[TBL] [Abstract][Full Text] [Related]
66. The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Huh JW; Min JJ; Lee JH; Kim HR; Kim YJ
Am J Clin Oncol; 2012 Aug; 35(4):340-4. PubMed ID: 21422901
[TBL] [Abstract][Full Text] [Related]
67. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
[TBL] [Abstract][Full Text] [Related]
68. Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials.
Weber WA; Gatsonis CA; Mozley PD; Hanna LG; Shields AF; Aberle DR; Govindan R; Torigian DA; Karp JS; Yu JQ; Subramaniam RM; Halvorsen RA; Siegel BA; ;
J Nucl Med; 2015 Aug; 56(8):1137-43. PubMed ID: 25908829
[TBL] [Abstract][Full Text] [Related]
69. Evaluating FDG uptake changes between pre and post therapy respiratory gated PET scans.
Aristophanous M; Yong Y; Yap JT; Killoran JH; Allen AM; Berbeco RI; Chen AB
Radiother Oncol; 2012 Mar; 102(3):377-82. PubMed ID: 22265731
[TBL] [Abstract][Full Text] [Related]
70. PET/CT reading for relapse in non-small cell lung cancer after chemoradiotherapy in the PET-Plan trial cohort.
Brose A; Michalski K; Ruf J; Tosch M; Eschmann SM; Schreckenberger M; König J; Nestle U; Miederer M
Cancer Imaging; 2023 May; 23(1):45. PubMed ID: 37198668
[TBL] [Abstract][Full Text] [Related]
71. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
72. Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy.
Watanabe S; Inoue T; Okamoto S; Magota K; Takayanagi A; Sakakibara-Konishi J; Katoh N; Hirata K; Manabe O; Toyonaga T; Kuge Y; Shirato H; Tamaki N; Shiga T
EJNMMI Res; 2019 Dec; 9(1):104. PubMed ID: 31802264
[TBL] [Abstract][Full Text] [Related]
73. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome?
Clarke K; Taremi M; Dahele M; Freeman M; Fung S; Franks K; Bezjak A; Brade A; Cho J; Hope A; Sun A
Radiother Oncol; 2012 Jul; 104(1):62-6. PubMed ID: 22682749
[TBL] [Abstract][Full Text] [Related]
74. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
75. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
76. Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy.
Fledelius J; Khalil A; Hjorthaug K; Frøkiær J
EJNMMI Res; 2016 Dec; 6(1):71. PubMed ID: 27655428
[TBL] [Abstract][Full Text] [Related]
77. The role of post-radiation therapy FDG PET in prediction of necessity for post-radiation therapy neck dissection in locally advanced head-and-neck squamous cell carcinoma.
Yao M; Graham MM; Hoffman HT; Smith RB; Funk GF; Graham SM; Dornfeld KJ; Skwarchuk M; Menda Y; Buatti JM
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1001-10. PubMed ID: 15234033
[TBL] [Abstract][Full Text] [Related]
78. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.
Groheux D; Giacchetti S; Espié M; Vercellino L; Hamy AS; Delord M; Berenger N; Toubert ME; Misset JL; Hindié E
J Nucl Med; 2011 Oct; 52(10):1526-34. PubMed ID: 21880576
[TBL] [Abstract][Full Text] [Related]
79. An exploratory study of volumetric analysis for assessing tumor response with (18)F-FAZA PET/CT in patients with advanced non-small-cell lung cancer (NSCLC).
Kerner GS; Bollineni VR; Hiltermann TJ; Sijtsema NM; Fischer A; Bongaerts AH; Pruim J; Groen HJ
EJNMMI Res; 2016 Dec; 6(1):33. PubMed ID: 27090118
[TBL] [Abstract][Full Text] [Related]
80. Local and regional treatment response by
van Diessen JNA; La Fontaine M; van den Heuvel MM; van Werkhoven E; Walraven I; Vogel WV; Belderbos JSA; Sonke JJ
Radiother Oncol; 2020 Feb; 143():30-36. PubMed ID: 31767474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
